journal article·2026-03Open access

Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure

Bo Zhu, Muhammad Aminu, Pingjun Chen, Jian‐Rong Li, Chuanpeng Dong, Chenyang Li, Yanhua Tian, Shao‐Wei Lu, Hong Chen, Chenxi Ma, Xin Hu, Jie Ye, Andrew Y. Liu, Beibei Huang, Frank R. Rojas, Parra Cuentas. Edwin Roger, Ou Shi, Monique B. Nilsson, Alissa Poteete, Khaja B. Khan, Wei Lu, Luisa M. Solis Soto, Junya Fujimoto, Cara Haymaker, Ignacio I. Wistuba, Zhubo Wei, Linghua Wang, Don L. Gibbons, Ken Chen, Alexandre Reuben, Jason M. Schenkel, John V. Heymach, Chao Cheng, Jia Wu, Jianjun Zhang

Advanced Science· Volume 13· Issue 17

Abstract

ABSTRACT Tumor evolution involves genetic, transcriptional, and phenotypic alterations that shape cancer cell behavior and interactions with the microenvironment. While single‐cell technologies have advanced our understanding of this process, spatial dynamics remain incompletely characterized. Here, whole‐exome sequencing (WES), imaging mass cytometry (IMC), and spatial transcriptomics (ST) were integrated to study molecular evolution and immune responses in two lung adenocarcinoma (LUAD) mouse models: a genetically engineered model (129S4/Sv‐Kras LSL‐G12D , termed 129S4 K) and a carcinogen‐induced precancer model (129S4 U). Compared to 129S4 K, 129S4 U tumors exhibited higher mutational, neoantigen but lower copy number variation (CNV) burdens at matched developmental timepoints, consistent with findings of higher mutational burden in human smoking‐related LUAD than nonsmoking LUAD. We profiled over 1.4 million spatial single cells from 284 IMC regions of interest and 51,531 spatial transcriptomic spots from 156 lesions across 141 mice. Macrophage abundance increased with tumor progression, while CD8 T‐cell and B‐cell densities declined in late‐stage LUAD. 129S4 U showed greater immune infiltration in both tumor and adjacent normal tissue, higher T‐cell cytotoxicity signature score in line with its higher mutational and neoantigen burdens. LUAD progression was marked by early morphological shifts and late‐stage changes in cell states and interactions. These data define spatial and genetic landscapes of LUAD development and provide a framework for investigating immune evolution and therapeutic strategies in early carcinogenesis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Single-cell and spatial transcriptomics · Cancer Immunotherapy and Biomarkers · Cancer Genomics and Diagnostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Departments of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

Genomic Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA

Imaging Physics The University of Texas MD Anderson Cancer Center Houston Texas USA

Institute for Data Science in Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

Translational Molecular Pathology The University of Texas MD Anderson Cancer Center Houston Texas USA

Department of Medicine Baylor College of Medicine Houston Texas USA

Department of Genetics Yale University School of Medicine New Haven Connecticut USA

Department of Cancer Systems Imaging The University of Texas MD Anderson Cancer Center Houston Texas USA

Clinical Research Center in Hiroshima Hiroshima University Hospital Hiroshima Japan

Department of Bioinformatics & Comp Biology The University of Texas MD Anderson Cancer Center Houston Texas USA

Funding

National Cancer Institute

References (68)

Show source-provided references
1. 10.3322/caac.2176310.3322/caac.21763 ↗
2. 10.1016/S0140‐6736(21)00312‐310.1016/S0140‐6736(21)00312‐3 ↗
3. 10.3390/ijms1904125910.3390/ijms19041259 ↗
4. 10.1001/jama.2021.2428710.1001/jama.2021.24287 ↗
5. 10.1056/NEJMoa121472610.1056/NEJMoa1214726 ↗
6. 10.1164/rccm.202101‐0119OC10.1164/rccm.202101‐0119OC ↗
7. 10.1016/j.jtho.2016.03.02510.1016/j.jtho.2016.03.025 ↗
8. Canakinumab Interception Trial and Preclinical Studies Reveal Stage‐Dependent Biology in Lung Cancer and Precancers
9. 10.1016/j.cell.2022.04.01510.1016/j.cell.2022.04.015 ↗
10. 10.1016/j.ccell.2020.06.01210.1016/j.ccell.2020.06.012 ↗
11. 10.1158/0008‐5472.CAN‐23‐012810.1158/0008‐5472.CAN‐23‐0128 ↗
12. 10.1038/s41467‐020‐17492‐y10.1038/s41467‐020‐17492‐y ↗
13. 10.1038/s41467‐021‐26770‐210.1038/s41467‐021‐26770‐2 ↗
14. 10.1038/s41467‐019‐10877‐810.1038/s41467‐019‐10877‐8 ↗
15. 10.1038/s41467‐021‐20907‐z10.1038/s41467‐021‐20907‐z ↗
16. 10.1016/j.cell.2024.03.01010.1016/j.cell.2024.03.010 ↗
17. 10.1038/nature1389810.1038/nature13898 ↗
18. 10.1038/nprot.2009.9510.1038/nprot.2009.95 ↗
19. 10.1101/gad.94300110.1101/gad.943001 ↗
20. 10.1016/j.ccr.2009.12.00810.1016/j.ccr.2009.12.008 ↗
21. 10.21037/tlcr.2018.06.0410.21037/tlcr.2018.06.04 ↗
22. 10.3389/fimmu.2021.69741210.3389/fimmu.2021.697412 ↗
23. 10.1016/j.ccell.2025.04.00310.1016/j.ccell.2025.04.003 ↗
24. 10.1038/s41556‐025‐01781‐z10.1038/s41556‐025‐01781‐z ↗
25. 10.1073/pnas.161360111310.1073/pnas.1613601113 ↗
26. 10.1038/s41586‐020‐1943‐310.1038/s41586‐020‐1943‐3 ↗
27. 10.1371/journal.pone.026714710.1371/journal.pone.0267147 ↗
28. The Chemical Constituents in Cigarettes and Cigarette Smoke: Priorities for Harm Reduction
29. 10.1038/s41467‐021‐22890‐x10.1038/s41467‐021‐22890‐x ↗
30. 10.1001/jamaoncol.2022.198110.1001/jamaoncol.2022.1981 ↗
31. 10.1016/j.isci.2023.10773210.1016/j.isci.2023.107732 ↗
32. 10.1038/nmeth.439110.1038/nmeth.4391 ↗
33. 10.1038/s41586‐019‐1876‐x10.1038/s41586‐019‐1876‐x ↗
34. 10.1016/j.ccell.2014.09.00610.1016/j.ccell.2014.09.006 ↗
35. 10.1016/j.cell.2019.05.03110.1016/j.cell.2019.05.031 ↗
36. 10.1093/carcin/16.5.106510.1093/carcin/16.5.1065 ↗
37. 10.1038/3507412910.1038/35074129 ↗
38. 10.1038/nature0603010.1038/nature06030 ↗
39. 10.1038/ng72110.1038/ng721 ↗
40. 10.1158/0008‐5472.CAN‐12‐090810.1158/0008‐5472.CAN‐12‐0908 ↗
41. 10.1016/j.ccell.2020.06.00610.1016/j.ccell.2020.06.006 ↗
42. 10.1038/s41586‐022‐05672‐310.1038/s41586‐022‐05672‐3 ↗
43. 10.3389/fonc.2020.0032410.3389/fonc.2020.00324 ↗
44. 10.3892/etm.2019.806810.3892/etm.2019.8068 ↗
45. 10.1164/rccm.201508‐1545CI10.1164/rccm.201508‐1545CI ↗
46. 10.1097/jto.0b013e3181f387e410.1097/jto.0b013e3181f387e4 ↗
47. 10.1038/s41571‐019‐0175‐710.1038/s41571‐019‐0175‐7 ↗
48. 10.1038/s41588‐020‐00752‐410.1038/s41588‐020‐00752‐4 ↗
49. 10.1158/2159‐8290.CD‐20‐052210.1158/2159‐8290.CD‐20‐0522 ↗
50. 10.1056/NEJMoa180194610.1056/NEJMoa1801946 ↗
51. 10.1126/science.aaa134810.1126/science.aaa1348 ↗
52. 10.1126/science.aad009510.1126/science.aad0095 ↗
53. 10.1016/j.cell.2019.10.02810.1016/j.cell.2019.10.028 ↗
54. 10.1007/s00262‐020‐02837‐910.1007/s00262‐020‐02837‐9 ↗
55. 10.1158/2159‐8290.CD‐18‐004410.1158/2159‐8290.CD‐18‐0044 ↗
56. 10.1016/j.jtho.2025.07.12110.1016/j.jtho.2025.07.121 ↗
57. 10.1136/jitc‐2021‐00289110.1136/jitc‐2021‐002891 ↗
58. 10.1038/s41568‐019‐0179‐810.1038/s41568‐019‐0179‐8 ↗
59. 10.1158/2159‐8290.CD‐18‐009910.1158/2159‐8290.CD‐18‐0099 ↗
60. 10.1158/2159‐8290.CD‐14‐123610.1158/2159‐8290.CD‐14‐1236 ↗
61. 10.1016/j.jtho.2023.09.13410.1016/j.jtho.2023.09.134 ↗
62. 10.1038/s41592‐021‐01358‐210.1038/s41592‐021‐01358‐2 ↗
63. 10.1038/s41587‐021‐01094‐010.1038/s41587‐021‐01094‐0 ↗
64. 10.1016/j.cell.2020.10.02110.1016/j.cell.2020.10.021 ↗
65. 10.1126/sciimmunol.abi507210.1126/sciimmunol.abi5072 ↗
66. 10.1016/j.modpat.2023.10032610.1016/j.modpat.2023.100326 ↗
67. 10.1038/s41586‐019‐0969‐x10.1038/s41586‐019‐0969‐x ↗
68. 10.1038/s41467‐021‐25960‐210.1038/s41467‐021‐25960‐2 ↗